Newly presented biomarker and clinical findings from the phase 2b PARADIGM trial of PrimeC informed the design of the global phase 3 PARAGON trial in ALS.
|Videos|May 28, 2020
CMSC 2020 Day 3: Laura Safar, MD on Use of Psychotropics in MS
Author(s)NeurologyLive® Staff
Laura Safar, MD, presents her lecture titled, "Use of Psychotropics in MS: Antidepressants, Anti-anxiety Agents, Mood Stabilizers, Hypnotics, Antipsychotics, and Cognitive Enhancers" as part of the 2020 CMSC Virtual Annual Meeting.
Advertisement
For more coverage from CMSC 2020,
To register for the 2020 CMSC Virtual Annual Meeting, May 26-29, 2020,
To complete the evaluation and claim credit, go to
Advertisement
Related to this article
Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.
QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.
uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.
Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.
AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.
Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.
Kim Henriksen, PhD, discusses research evaluating blood-based biomarkers of blood-brain barrier remodeling and immune cell activity in multiple sclerosis, including their potential to track treatment responses and inform future biomarker development.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
ALS Agent Dazucorilant Associated With Lower 2-Year Mortality in Exploratory DAZALS Analysis
2
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA, Sevasemten Misses Primary, Secondary End Points in BMD, Overviewing the 1-Year KYSA-8 Findings
3
QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS
4
Gray Areas: Is Preventing Frailty in Multiple Sclerosis a Realistic Goal?
5